Life Sciences Archive » February, 2009

Life Sciences - February, 2009

143 articles

• Amgen, Wyeth To Fight Suit Over Aranesp, Enbrel
• Regulatory Oversight In Health Care
• Mannatech Settles Texas AG Fraud Probe For $6M
• Stryker Tries To Quash Antitrust Class Actions
• Investors, NPS Pharma Strike $15M Deal In Preos Suit
• Vapor Intrusion: New Exposures, Old Sites
• Novartis Unit To Appeal $47.1M Contact Lens Ruling
• Abbott Lied About Rival's Infant Formula: Suit
• Obama's 2010 Budget Seeks $1B For Food Safety
• Novo Seeks To Halt Caraco Launch Of Generic Prandin
• Aurobindo USA Can't Get Out Of Crestor MDL: Judge
• AstraZeneca To Make Seroquel Label Changes
• Obama Touts Generic Biologics To Lower Drug Costs
• FDA Requires Black Box Warning For GI Drug
• Judge Nixes Expired Product Suit Against Rite Aid
• FDA Says Ranbaxy Falsified Data From India Plant
• KV Targets Citigroup Over $72M In Illiquid ARS
• The Scope Of Fraud In Multiclass Registrations
• MedImmune Keeps Up Fight Against Generic Ethyol
• Fed. Circ. Affirms Stay Extension In Evista Dispute
• AntiCancer Takes New Shot At Rival Over Patents
• No New Trial For Applied In Covidien IP Spat: Court
• Judge Strikes J&J Invalidity Contentions In Stent Suit
• Diagnosing Section 1 Violations
• Teva Loses Bid To Toss Novartis Claims Over Famvir
• US Unseals FCA Suit Over Lexapro, Celexa
• Tainted Syringes Spark International Manhunt
• Ala. Jury Hits Sandoz For $78M In Medicaid Fraud Suit
• Ill. AG Sues Caterpillar Over Oil-Waste Spill
• Buyer Class Still Valid In Nifedipine Antitrust Suit
• Judge Rejects Interest For Lowey In Bayer Settlement
• Eye Surgery Antitrust Suit Against Alcon Dismissed
• 1st Circ. Refuses To Rehear Dispute Over Visudyne
• Fentora Patent Suit Just A Delay Tactic: Barr
• PCB Case Against Monsanto Remanded To State Court
• Adverse Event Reporting To The IRB
• Allergan Patent For Zymar Not Valid: Apotex
• Judge Keeps TriCor Competition Suit Alive
• High Court Refusal Lets Lexapro Patent Suit Continue
• C&D, Abbott $29M Pregnancy Test Patent Suit Ended
• Appropriations Bill Calls For $335M Increase To FDA
• Epilepsy Drug Linked To Blood Disorder: FDA
• What's Next For Physician-Owned Hospitals?
• Ex-Stryker Sales Rep Pleads Guilty To Misbranding
• Judge Tosses Suit V. Funds Over Attorney Conduct
• Cardinal Reaches Deal With FDA Over Drug Pumps
• BMS Settles Container Patent Suit Against Abbott
• Fed. Circ. Reopens Enzo DNA Detection Patent Case
• Fed. Circ. Takes On Prior Claim Construction Issue
• Deaths Prompt Warnings On Psoriasis Drug Raptiva
• Generic Patent Challenges Up 19% In '08: Report
• Endo, Actavis Settle Spat Over Painkiller Patents
• Rescuecom And Keyword Advertising Issues
• Lawmakers Demand Information On Vytorin Trials
• DOJ Joins Qui Tam Suits Over Off-Label Natrecor Use
• Amphastar Antitrust Claims Nixed In Lovenox Suit
• Medtronic Wins On Preemption In Wis. High Court
• Fictional Characters, Storytelling And Patent Trials
• 11 Fla. Cases Settled In Fen-Phen MDL V. Wyeth
• Pfizer Unit May Have To Pay $153M In Fraud Case
• Meth Epidemic: Invitation To Social Engineering
• Medtronic Counsel Returns To Oppenheimer Wolff
• Tech-Based Venues Pushing Rocket Dockets Aside
• Wiley Rein Scores WilmerHale FDA Policy Guru
• Ariad Faces Derivative Suit After Directors Cut Ties
• Advanced Medical Optics Investor Sues Over Merger
• 3rd-Party Payers In Guidant Case Seek Appeal
• Baxter Wins Round In Dialysis Machine Patent Suit
• Medtronic MDL Judge's Son Linked To Company
• AAI Protests Pfizer-Wyeth Merger
• Acacia Unit, Edwards Settle Catheter Patent Suit
• Spain Recalls Gardasil Batch After Illnesses
• Fed. Claims Court Finds No Vaccines-Autism Link
• Zicam Maker Targeted In IP Suit Over Cold Remedy
• 7th Circ. Upholds Evidence Limits In Effexor Suit
• Medical Cos.' Success With Riegel May Be Short-Lived
• CSX Units Must Pay For NJ River Cleanup: 3rd Circ.
• Novartis, Par Settle Patent Suit Over Lotrel
• Judge Accuses Stryker Of Warped Riegel Reading
• Bristol-Myers, IBM Agree To $14M Superfund Cleanup
• Fraud Claims Live Against Biovail Execs In SEC Case
• Judge Decertifies Class In Off-Label Neurontin Suit
• Harry And David Sues Rival Over Keyword Trigger
• The Modern Reality Of The FCPA
• Judge OKs Partial Class Status In ERISA Suit V. Merck
• Judge Slams Plaintiffs' Experts In Nixing Seroquel Suit
• Fed. Circ. Nixes $2M Ruling V. Bath & Body Works
• Protein From Engineered Goats Wins FDA Approval
• King & Spalding Nabs 3 Baker Botts IP Partners
• The Problem With IMS Health V. Ayotte
• 27 State AGs, Bayer Strike Deal Over Yaz Ads
• Top Motions In An IP Case And How To Win Them
• Leahy Discloses Plan To Reintroduce Patent Reform
• Globalization Could Incite Global Forum Shopping
• Berkshire Hathaway Cos. Hit With RICO Suit
• Life Sciences Practice: Reed Smith
• Medtronic Stent Patent Claims Not Indefinite: Judge
• Federal Preemption Shifting, Not Dead: Experts
• FDA Seeks Stronger Safeguards For Addictive Opioids
• Deferred Prosecution Deals Dip Sharply In 2008
• Pfizer Commits To Physician Payment Disclosures
• PerkinElmer Sues To Nix Down Syndrome Test Patent
• Alternative Electrodes' Antitrust Claims Kept Alive
• 'Ordinary' Skill In The Art After KSR
• Anticipated Policy Shift For Stem Cell Research
• Obviousness Of Enantiomers After KSR
• SciCo Fights Boston Scientific Sanctions Bid In IP Suit
• Quinn Emanuel Picks Up 3 IP Partners
• Drug Co. Gets OK To Fight Damages In Seroquel MDL
• Dismissed Medtronic MDL Could Get New Lease On Life
• Cordis Hit With $22M Verdict In Stent Patent Case
• Securities Suit Against Baxter Gets The Boot
• K-Dur Reverse Payment Legal: Special Master
• Lawyers Eye Seeds Of Litigation Wave In Layoffs
• Injunctions And Medical Devices
• KV Halts Prenatal, Iron Supplements In 4th Recall
• House Weighs Food Safety Bills As Fears Grow
• Abbott Denied Stay In Cordis Stent Spat
• Top Sens. Target Drug Cos.' Pay-For-Delay Deals
• Prioritizing Patents For Stem Cell Inventions
• 3 Private Actions Fight AndroGel Reverse Payments
• EU To Post Comments On Drug Sector Antitrust Probe
• Indevus, Endo Face Another Class Action Over Merger
• Zimmer Files Lawsuit Over Bone Screw Patent
• The FTC Pursuit Of Supreme Court Strategy
• Alcon Sues Apotex, Sandoz Over Eyedrops Patents
• BSC Accuses SciCo Of Evidence Tampering
• Biovail Founder Fined $1M In SEC Fraud Suit
• Bhopal Case May Be Mediated By Sept. 11 Lawyer
• BSC Told To Pay Interest On $19M Medtronic Award
• Judge Keeps Alive Dey's Fight For Xopenex ANDA
• Coughlin Stoia Attys Seek $18M In Celexa Deal Fees
• FTC, Calif. Launch Reverse Payment Challenge
• Quigley Tries To Bury The Hatchet With Insurers
• Pfizer To Face Securities Fraud Suit Over Celebrex
• Sonnenschein Nabs Leader, Counsel For FDA Group
• KCI Vacuum Patents Valid, Uninfringed: Fed. Circ.
• Recession-Proofing: IP Is Key
• Genzyme Sued As Gene Therapy Pact Falls Apart
• CVS Assistant Managers Sue For Overtime Pay
• Regulating Off-Label Info On Drugs, Medical Devices
• The Significance Of Takeda V. Mylan
• Restoring Science To Its Rightful Place In America